Skip to main content
Signal8

BioNexus Gene Lab Corp (BGLC) Form 10-Q — May 15, 2026

$BGLCForm 10-QFiled May 15, 2026, 5:15 PM ET0001477932-26-003242Original filing

BioNexus Gene Lab Corp (BGLC) reported a 99% year-over-year revenue collapse to $22,842 for Q1 2026, driven by a near-total halt in operations at its Chemrex subsidiary following governance failures. The company recorded a net loss of $543,575 and disclosed a material weakness in internal controls, citing unauthorized transactions by former Chemrex management that led to a $2.94 million demand for repayment. Despite the operational distress, BGLC highlighted strategic capital initiatives, including a $500 million equity purchase agreement with ARC Group International and an effective $20 million ATM facility with Maxim Group.

Key figures

Revenue
22842
Total Assets
9040130
Cash Position
2397977
Shares Outstanding
2417314
Atm capacity usd
20000000
Fidelion stake percent
15
Atm proceeds to date usd
267311
Fidelion license fee usd
2000000
Chemrex demand amount usd
2944000
Arc facility commitment usd
500000000
Arc commitment shares issued
175000
Bglc shares issued to fidelion
392329

Price after filing

1 day: 0.0%7 days: +2.0%30 days: +6.6%

Close on the filing date to close N calendar days later (from $1.98). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.